Organon & Co.

NYSE: OGN · Real-Time Price · USD
8.23
-0.49 (-5.62%)
At close: May 06, 2025, 11:38 AM
-5.62%
Bid 8.23
Market Cap 2.14B
Revenue (ttm) 4.78B
Net Income (ttm) 663.09M
EPS (ttm) 2.88
PE Ratio (ttm) 2.86
Forward PE 2.38
Analyst Hold
Ask 8.24
Volume 4,561,634
Avg. Volume (20D) 4,859,386
Open 8.61
Previous Close 8.72
Day's Range 8.19 - 8.66
52-Week Range 8.19 - 23.10
Beta 0.69

About OGN

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology pr...

Sector Healthcare
IPO Date May 14, 2021
Employees 10,000
Stock Exchange NYSE
Ticker Symbol OGN
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for OGN stock is "Hold." The 12-month stock price forecast is $20, which is an increase of 142.87% from the latest price.

Stock Forecasts

Earnings Surprise

Organon & has released their quartely earnings on May 1, 2025:
  • Revenue of $1.51B exceeds estimates by $3M, with -6.72% YoY decline.
  • EPS of 1.02 exceeds estimates by 0.13, with -16.39% YoY decline.
  • 21 hours ago
    -9.07%
    Organon shares are trading lower after Morgan Stan... Unlock content with Pro Subscription
    5 days ago
    -26.91%
    Organon shares are trading lower after the company reported Q1 financial results and cut its quarterly dividend.